The management of acid-related disorders: the burden of disease and the need for effective treatment

References

• OHE compendium of health statistics, 10th edition, London: Office of Health Economics; 1997.
   Google Scholar
• Social Security Statistics, Department of Social Services, UK.
   Google Scholar
• Office of Population Censuses and Surveys. Morbidity statistics from general practice, fourth national study 1991/92 (Series MB5 (3)). London: HMSO; 1995.
   Google Scholar
• Talley NJ, Colin-Jones D, Kock KL, et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145 – 160.
   Google Scholar
• Talley NJ. Dyspepsia and heartburn: a clinical challenge. Aliment Pharmacol Ther 1997; 11 (suppl. 2): 1 – 8.
   Google Scholar
• Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996; 10: 83 – 9.
   PubMed Web of Science ®Google Scholar
• Jones RH, Lydeard SE, Hobbs FDR, et al. Dyspepsia in England and Scotland. Gut 1990; 3: 401 – 5.
   Google Scholar
• Nyrén O, Lindberg G, Lindström E, et al. Economic cost of functional dyspepsia. PharmacoEconom 1992; 1: 312 – 14.
   PubMedGoogle Scholar
• Grainger SL, Klass HJ, Rake MO, et al. Prevalence of dyspepsia: the epidemiology of overlapping symptoms. Postgrad Med J 1994; 70: 154 – 61.
   PubMed Web of Science ®Google Scholar
• Glise H, Wiklund I. Measurement of the impact of heartburn and dyspepsia on quality of life. Aliment Pharmacol Ther 1997; 11 (suppl 2): 73 – 7.
   Google Scholar
• Agréus L, Talley N. Challenges in managing dyspepsia in general practice. BMJ 1997; 315: 1284–8.
   PubMedGoogle Scholar
• Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116–28.
   Google Scholar
• International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans: vol. 61. Lyon: IARC: 1994.
   Google Scholar
• European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997; 41: 8 – 13.
   PubMedGoogle Scholar
• Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 (suppl 1): 24–9.
   PubMed Web of Science ®Google Scholar
• Corder AP, Jones RH, Millward Sadler GH, et al. Heartburn, oesophagitis and Barrett’s oesophagus in self-medicating patients in general practice. Br J Clin Pract 1996; 50: 245 - 8.
   PubMedGoogle Scholar
• Jones RH, Hungin APS, Phillips J, et al. Gastro-oesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995; 1: 149–54.
   Google Scholar
• Stoker DL, Williams JG, Leicester RG. Oesophagitis - a five year review. Gut 1988; 29: A1450.
   Web of Science ®Google Scholar
• Gear MWL, Wilkinson SP. Open-access upper alimentary endoscopy. Br J Hosp Med 1989; 41: 438 – 44.
   PubMed Web of Science ®Google Scholar
• DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med 1995; 155: 2165–73.
   PubMedGoogle Scholar
• Smout AJPM. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 1997; 11 (suppl 2): 81–5.
   Google Scholar
• Green JRB. Is there such an entity as mild oesophagitis? Eur J Clin Res 1993; 4: 29–34.
   Google Scholar
• Galmiche J-P, Bruley des Varannes S. Symptoms and disease severity in gastro-oesophageal reflux disease. Scand J Gastroenterol 1994; 29 (suppl 201): 62–8.
   Google Scholar
• Carlsson R, Frison L, Lundell L, et al. Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis. Gastroenterology 1996; 110 (suppl): A77.
   Google Scholar
• Dent J. Management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11 (suppl 2): 99–105.
   Google Scholar
• Decktor DL, Robinson M, Rodriguez SL, et al. H2-receptor antagonist tolerance and gastroesophageal reflux disease: an assessment of intraesophageal and intragastric pH during 28 days of standard therapy. Gastroenterology 1993; 104: A64.
   Google Scholar
• Hurlimann S, Abbühl B, Inauen W, et al. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193–201.
   PubMedGoogle Scholar
• Bate CM, Keeling PWN, O’Morain C, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 1990; 31: 968–72.
   PubMed Web of Science ®Google Scholar
• Venables T, Newland R, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965–73.
   PubMed Web of Science ®Google Scholar
• Bate CM, Green JRB, Axon ATR, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997; 11: 755–63.
   PubMed Web of Science ®Google Scholar
• Lauritsen K. Management of endoscopy-negative reflux disease: progress with short-term treatment. Aliment Pharmacol Ther 1997; 11 (suppl 2): 87–92.
   Google Scholar
• Green JRB, Venables TL, Bate CM, et al. Omeprazole produces a greater improvement in quality of life than placebo, antacid-alginate, ranitidine, cimetidine or cisapride in patients with gastro-oesophageal reflux disease. Br J Med Econ 1997; 11: 121 – 31.
   Google Scholar
• Chiba N, de Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in Grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798–1810.
   PubMed Web of Science ®Google Scholar
• Lundell L. New information relevant to long-term management of endoscopy-negative reflux disease. Aliment Pharmacol Ther 1997; 11 (suppl 2): 93–8.
   Google Scholar
• Sontag S. Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 93 - 312.
   Google Scholar
• Lundell L. Long-term treatment of gastro-oesophageal reflux disease with omeprazole. Scand J Gastroenterol 1994; 29 (suppl 201): 74–8.
   Google Scholar
• Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106–10.
   PubMed Web of Science ®Google Scholar
• Carlsson R, Galmiche J-P, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473–82.
   PubMedGoogle Scholar
• Bate CM, Green JRB, Axon ATR, et al. Omeprazole is more effective than cimetidine in the prevention of GORD-associated heartburn and the occurrence of underlying oesophagitis. Aliment Pharmacol Ther 1998; 12: 41 – 7.
   PubMedGoogle Scholar
• Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907–15.
   PubMed Web of Science ®Google Scholar
• Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994; 107: 1312–18.
   PubMed Web of Science ®Google Scholar
• Jaspersen D, Schwacha H, Schorr W, et al. Omeprazole and complicated gastro-oesophageal reflux disease. J Gastroenterol Hepatol 1996; 11: 900–2.
   PubMedGoogle Scholar
• Jaspersen D, Diehl KL, Schoeppner H, et al. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998; 12: 49–52.
   PubMedGoogle Scholar
• Damman HG, von zur Muchlen A, Balks HJ, et al. The effects of lansoprazole 30 or 60 mg daily on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther 1993; 7: 191 – 6.
   PubMedGoogle Scholar
• Koop H, Kuly S, Flüg M, et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol 1996; 8: 915–18.
   PubMedGoogle Scholar
• Seensalu R, Iwarzon M, Janozewska L, et al. Dose response comparison of lansoprazole and omeprazole on 24-hour gastric acidity and plasma gastrin in healthy volunteers. Gastroenterology 1995; 108 (4 Pt 2): A215.
   Google Scholar
• Geus WP, Nicolai JJ, van den Boomgaard DM, et al. Comparison of acid inhibitory effects of omeprazole 20mg od and bd with lansoprazole 30mg od and bd in H. pylori-negative healthy controls. Gastroenterology 1997; 112 (4 Pt 2): A125.
   Google Scholar
• Bate CM. Cost effectiveness of omeprazole in the treatment of reflux oesophagitis. Br J Med Econ 1991; 1: 53 – 61.
   Google Scholar
• Hillman AL. Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease. Scand J Gastroenterol 1994; 29 (suppl 201): 98 -102.
   Google Scholar
• Bate CM, Hungin APS, Wilcock C, et al. Cost effective management of gastroesophageal reflux disease in general practice. Br J Med Econ 1993; 6: 81–90.
   Google Scholar
• Jönsson B, Stålhammer N-O. The cost effectiveness of omeprazole and ranitidine in intermittent and maintenance treatment of reflux oesophagitis - the case in Sweden. Br J Med Econ 1993; 6: 111 – 26.
   Google Scholar
• Bate CM, Richardson PDI. Cost effectiveness of omeprazole in the management of gastroesophageal reflux disease in clinical practice. Br J Med Econ 1994; 7: 81–97.
   Google Scholar
• Green JRB, Bate CM, Copeman MB. A comparison of the cost-effectiveness of omeprazole and ranitidine in reflux oesophagitis. Br J Med Econ 1995; 8: 157 -60.
   Google Scholar
• Phillips C, Moore A. Trial and error - an expensive luxury: economic analysis of effectiveness of proton pump inhibitors and histamine antagonists in treating reflux disease. Br J Med Econ 1997; 11: 55 – 63.
   Google Scholar
• Holt S, Howden CW. Omeprazole overview and opinion. Dig Dis Sci 1991; 36: 385–93.
   PubMed Web of Science ®Google Scholar
• Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590–8.
   PubMedGoogle Scholar
• Bodger K, Daly MJ, Heatley RV. Clinical economics review: Helicobacter pylori-associated peptic ulcer disease. Aliment Pharmacol Ther 1997; 11: 273–82.
   PubMedGoogle Scholar
• Office for National Statistics. Mortality statistics, 1995. (Series DH2 (22)). London: HMSO.
   Google Scholar
• Tytgat GNJ. Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359–68.
   PubMed Web of Science ®Google Scholar
• Data on file (Astra Pharmaceuticals Ltd. Gen/001/Dec1997).
   Google Scholar
• Bell GD, Powell KU, Burridge SM, et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 41–6.
   PubMed Web of Science ®Google Scholar
• Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobials - the MACH1 study. Helicobacter 1996;1:138 -44.
   Google Scholar
• Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223 - 43.
   PubMed Web of Science ®Google Scholar
• Reilly TG, Ayres RCS, Poxon V, et al. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcers. Aliment Pharmacol Ther 1995; 9: 483–90.
   PubMed Web of Science ®Google Scholar
• Campbell LM. The role of Helicobacter pylori eradication regimen (omeprazole plus amoxycillin) in the long-term management of ulcer-like dyspepsia in general practice. Br J Med Econ 1994; 7: 147–53.
   Google Scholar
• Cottrill MRB. The prevalence of Helicobacter pylori infection in patients receiving long-term H2-receptor antagonists in general practice: clinical and financial consequences of eradication using omeprazole plus amoxycillin or “triple therapy”. Br J Med Econ 1994; 7: 35–41.
   Google Scholar
• Deltenre M, Jönsson B. Pharmacoeconomics. Curr Opin Gastroenterol 1996; 12 (suppl 1): 45–9.
   Google Scholar
• Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a multicentre comparative trial. Gut 1997; 41: 735 – 9.
   PubMedGoogle Scholar
• Phillips C, Moore A. Implementing evidence-based medical interventions: the cost-effectiveness of Helicobacter pylori diagnosis and eradication. Br J Med Econ 1996; 10: 47 – 57.
   Google Scholar
• Hastings LA, Bell GD, Powell KU, et al. Impact of Helicobacter pylori eradication on the prescribing of ulcer-healing drugs in the treatment of peptic ulcer disease in general practice. Br J Med Econ 1997; 11: 45–53.
   Google Scholar
• Phull PS, Ryder SD, Halliday D, et al. The economic and quality of life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease: a community-based study. Postgrad Med J 1995; 71: 413–18.
   PubMedGoogle Scholar
• Hirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2: 207–23.
   PubMedGoogle Scholar
• Hawkey CJ. Non-steroidal antiinflammatory drugs and peptic ulcers. BMJ 1990; 300: 278 – 84.
   PubMed Web of Science ®Google Scholar
• Myerson RM. NSAID-associated gastroduodenal damage. J Pharm Med 1992; 2: 277–84.
   Google Scholar
• Fries JF, Miller SR, Spitz PW, et al. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990; 17 (suppl 20): 12 – 19.
   Google Scholar
• Walan A, Bader J-P, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69–75.
   PubMedGoogle Scholar
• French PC, Darekar BS, Mills JG, et al. Ranitidine in the prevention of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulceration in arthritic patients. Eur J Gastroenterol Hepatol 1994; 6: 1141–7.
   Google Scholar
• Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241–9.
   PubMed Web of Science ®Google Scholar
• Ching CK, Lam SK. A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease. J Gastroenterol 1995; 30: 607–14.
   PubMedGoogle Scholar
• Hawkey CJ, Floren I, Långström G, et al. Omeprazole vs misoprostol: different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users - the OMNIUM study. Gastroenterology 1997; 112 (suppl): A144.
   Google Scholar
• Yeomans ND, Långstrom G, Naesdal J, et al. Omeprazole versus ranitidine for healing of NSAID-associated ulcers and erosions in relation to H. pylori status - the ASTRONAUT study. Gastroenterology 1997; 112: A338.
   Google Scholar
• Yeomans ND, Swannell AJ, Eriksson S, et al. Healing of NSAID-associated ulcers and erosions: superiority of omeprazole over ranitidine. Gastroenterology 1996; 110: A303.
   Google Scholar
• Wiklund I, Swannell AJ, Yeomans ND, et al. Quality of life (QoL) in patients with non-steroidal anti-inflammatory drug (NSAID) associated gastroduodenal lesions during healing and maintenance. Gut 1996; 39 (suppl 1): A32.
   Google Scholar
• Ekström P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal antiinflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753 – 8.
   PubMed Web of Science ®Google Scholar
• Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for NSAID users. Gastroenterology 1996; 110: A86.
   Google Scholar
• Yeomans ND, Swannell AJ, Walan A, et al. Direct comparison of omeprazole and misoprostol as maintenance treatment for NSAID-associated gastroduodenal ulcers, erosions and symptoms. Rheum Eur 1996; 25 (suppl 1): 80.
   Google Scholar
• Hawkey CJ, Swannell AJ, Eriksson S, et al. Lower frequency of gastroduodenal ulcers and erosions and dyspeptic symptoms in NSAID users during maintenance with omeprazole compared to ranitidine. Gastroenterology 1996; 110: A131.
   Google Scholar